Core Insights - The article emphasizes the importance of strategic financial planning for retirement, focusing on capital allocation to businesses with strong financials and reliable earnings to ensure a comfortable retirement [7][8] - It highlights the need for a balanced approach that includes both stable income and moderate growth to combat inflation and maintain purchasing power over an extended retirement period [7][8] Retirement Planning - The average life expectancy in the country is 81.2 years, indicating that retirees may need to plan for potentially two decades of retirement [2] - A stable income from investments is essential, but there is also a need for growth in the portfolio to keep pace with inflation [2] Investment Characteristics - Key characteristics of a retirement portfolio should include durable businesses, strong balance sheets, high-quality non-cyclical earnings, and safe, growing dividends [2] - Retirees often make the mistake of chasing high dividend yields without considering the associated risks, as seen in companies like Altria and British American Tobacco [2][3] Portfolio Construction - A sample retirement portfolio is constructed with a projected yield of 5%, generating an annual income of $50,133 before taxes [6] - The portfolio includes a mix of individual stocks and one ETF for diversification, focusing on companies with strong dividend growth and capital appreciation potential [4][6] Individual Stock Analysis - Schwab US Dividend Equity ETF is highlighted for its sustainable and high-quality dividends, with a return on equity of 37.3% [6] - Enterprise Products Partners offers a stable business model with a distribution yield of 7.85% and expected EPS growth of 5% annually [6] - Realty Income is noted for its stable business model and diversified tenant base, providing a 5.8% dividend yield [6] - Allianz, the only European stock in the portfolio, has a solid dividend yield of 4.7% and is expected to grow its EPS by 6.3% over the next three years [6] - AbbVie, despite facing challenges, has a diversified portfolio and a 3.6% dividend yield with expected growth of 6.5% [6] - NextEra Energy is recognized for its commitment to clean energy and a well-covered dividend yield of 3.32% [6] - Ares Capital, as a Business Development Company, offers a high dividend yield of 9.6% but has seen a decrease in distribution [6] - Texas Instruments is noted for its strong dividend growth of 12.8% over the past five years [6] - PepsiCo and McDonald's are highlighted as defensive picks, with steady growth and reliable dividends [6] Conclusion - The article concludes that achieving financial freedom and a comfortable retirement is possible through careful planning and strategic investment in quality businesses [8]

Investors know the phrase “let your winners run,” but it’s easier said than done. The temptation to take profits off the table is often too great to ignore. By doing so, however, we run the risk of undercutting our portfolio returns. Having said that, you can’t go wrong with these stocks that just hit 52-week highs. There are quite a few winning stocks at 52-week highs that investors should continue to let run. The following three stocks may be at new peaks, but they have plenty of room to move higher still ...

Catherine Ledner/Stone via Getty Images Foreword As a supplement to this article, please note that Kiplinger has published an on-line slide-show detailing the latest 2024 S&P Dividend Aristocrats. The article, entitled The S&P 500 Dividend Aristocrats, is by Dan Burrows, a contributing editor. S&P Dow Jones Indices rebalances the S&P 500 Dividend Aristocrats every January; the Aristocratic population now stands at 67. There were two changes to the Dividend Aristocrats announced in January 2024. Walgreen ...

AbbVie to maintain exclusive access to Calibr-Skaggs' switchable CAR-T (sCAR-T) platform to develop novel cell therapy candidates against solid tumor targets identified by AbbVie AbbVie also has the option to explore the applicability of Calibr-Skaggs' sCAR-T platform in autoimmune diseases Calibr-Skaggs to partner with AbbVie to support discovery of next-generation sCAR-Ts using genetic medicine-based approaches LA JOLLA, Calif., Feb. 6, 2024 /PRNewswire/ -- The Calibr-Skaggs Institute for Innovative Med ...

AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Over the past month, shares of this drugmaker have returned +6.1%, compared to the Zacks S&P 500 composite's +5.3% change. During this period, the Zacks Large Cap Pharmaceuticals industry, which AbbVie falls in, has gained 4.6%. The key question now is: What could be the stock's future direction?Although media reports ...

Investing in dividend stocks is generally reserved for those who prefer steady returns and low volatility over the thrill of rapid potential gains. Investors saw tech stocks explode in 2023 as artificial intelligence emerged. In 2024, investors expect further growth but are also hesitant.Economists believe that a soft landing is the most likely scenario. Let’s all hope that that’s the case. However, it also makes sense to bolster your portfolio simultaneously with the safety of dividend stocks.As with all o ...

Whether it's through stocks, bonds, ETFs, or other types of securities, all investors love seeing their portfolios score big returns. But when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.Cash flow can come from bond interest, interest from other types of investments, and of course, dividends. A dividend is the distribution of a company's earnings paid out to shareholders; it's often viewed by its dividend yield, a metric that measures ...

cagkansayin Introduction It's time to talk about one of my favorite dividend investments. A company that has both an elevated yield of 3.7% and consistent dividend growth, making it a great investment for a very wide range of investors. That company is AbbVie (NYSE:ABBV), a stock I covered on November 29 in an article titled 4.5%-Yielding AbbVie Is One Of My Favorite Value Plays For 2024." Here's a part of the takeaway I used back then: Despite the prevailing underperformance of value stocks since 20 ...

Income-seeking investors usually don't think of the innovation-dependent pharmaceutical industry as a place to look for businesses with reliable cash flows.Dividend seekers have a good reason to be cautious regarding drugmaker stocks. Profit driven by patent-protected market exclusivity can disappear in the blink of an eye after those patents expire. These two giants of the pharmaceutical industry are made of enough moving pieces that when one blockbuster falls off a patent cliff, there's another on deck to ...

Key TakeawaysAbbVie Inc. reported profit and sales that beat estimates, and raised its guidance on two of its key drugs.The pharmaceutical company's revenue was fueled by immunology treatments Skyrizi and Rinvoq.AbbVie said it now anticipates Skyrizi and Rinvoq will bring in sales of $27 billion by 2027.AbbVie Inc. (ABBV) shares traded near their all-time high Friday as the pharmaceutical company posted better-than-expected results and raised its sales forecast for two of its key medicines.AbbVie reported f ...